Journal of Clinical and Experimental Ophthalmology
Open Access

Lifitegrast and other new topical medications for dry eye disease

2^nd International Conference on Eye and Vision

September 26-28, 2016 Orlando, USA

Rolando Toyos

Toyos Clinic, USA

Scientific Tracks Abstracts: J Clin Exp Ophthalmol

Abstract :

Over the last few years, more companies are spending more research dollars in developing new medications for dry eye disease (DED). We have completed and have several on going studies on different drops specifically designed for DED. Recently a medication, lifitegrast was approved. Lifitegrast is an anti-inflammatory drop that inhibits the binding of LFA-1 to ICAM-1 down-regulating the inflammation mediated by T lymphocytes. It is the only medication FDA approved for the signs and symptoms of DED. We will present FDA and our current research of this novel drop. We will also cover our work with platelet rich plasma eye drops, optimel, and oculocin. All work will include OSDI data, TBUT, and effects on lid margin disease.

Biography :

Rolando Toyos is the Medical Director and Founder of Toyos Clinic. He completed his Bachelor’s and Master’s degrees from The University of California, Berkeley and Stanford University. Prior to Medical School, he was National High School Teacher of the Year. He completed his Medical degree at the University of Illinois where he was Class President and a James Scholar. He completed his Ophthalmology Residency at North-western University and Chicago Children’s Hospital before starting Toyos Clinic. He has published several books and research articles, lecturing internationally on scientific topics such as his invention Intense Pulse Light for Dry Eye.

Email: rostar80@gmail.com